- Company
- Hanmi and Samsung Bioepis join forces to sell Prolia similar
- by Cha, Jihyun Mar 20, 2025 06:01am
- Hanmi Pharmaceutical and Samsung Bioepis announced on the 19th that they had signed a joint sales agreement on the 18th for the domestic launch of the osteoporosis treatment Prolia biosimilar (Project name: SB16, ingredient name: denosumab) in Korea. Under the agreement, Samsung Bioepis is responsible for the production and supply of the
- Company
- Will COVID-19 vaccines be added to the NIP this year?
- by Whang, byung-woo Mar 20, 2025 06:00am
- As the government began the process of reviewing the inclusion of COVID-19 vaccines in the National Immunization Program (NIP) list, attention has been drawn to whether COVID-19 would be included in the NIP list within this year. According to industry sources on March 20, the Korea Disease Control and Prevention Agency (KDCA) and major pha
- Company
- Pfizer’s Elrexfio fails to pass CDDC's reimb review in KOR
- by Eo, Yun-Ho Mar 20, 2025 06:00am
- New treatment options in the field of multiple myeloma are having difficulty receiving reimbursement listing in Korea. Following the rejection of Janssen Korea’s ‘Tecvayli (teclistamab)' in November last year, Pfizer Korea's ‘Elrexfio (elranatamab)' also failed to pass the Health Insurance Review and Assessment Service's Cancer Disease
- Policy
- Public-private meetings on improving drug pricing system
- by Lee, Tak-Sun Mar 20, 2025 06:00am
- Attention has been gathered to recent public-private meetings regarding improving drug pricing system. This month, a public-private discussion session hosted by the Ministry of Health and Welfare (MOHW) and a meeting to discuss the negotiation system for expanded use of scope were held. On March 26, a regular meeting session was attende
- Company
- Will the monthly ₩20M Welireg be reimbursed this time?
- by Moon, sung-ho Mar 20, 2025 05:59am
- MSD Korea is re-applying for reimbursement of the rare anticancer drug ‘Welireg,’ following the re-application for reimbursement of its Keytruda Results of the first hurdle, whether the Cancer Disease Review Committee sets a reimbursement standard, are expected to determine the fate of the drug’s quick reimbursment. According to in
- Company
- GC Cell sells its Japanese bio stock to associated companies
- by Cha, Jihyun Mar 19, 2025 06:02am
- GC Group's subsidiary, GC Cell, has transferred some shares of its Japanese cell therapy company, which it acquired seven years ago, to a holding company that specializes in gene analysis within the group. The company decided that entrusting a business to a local subsidiary with business experience in the Japanese market would be more efficie
- Company
- A company that cares about employee well-being
- by Whang, byung-woo Mar 19, 2025 06:02am
- Medtronic, which was founded in Minneapolis, Minnesota, USA in 1949, has been expanding its influence in Korea for 37 years since it opened a liaison office in Korea in 1987 and established a corporation in 2000. Medtronic is currently focusing on four areas: cardiovascular, neuroscience, medical-surgical, and diabetes, with 500 Korean em
- Company
- Takeda Korea appoints Kwang-gyu Park as new General Manager
- by Whang, byung-woo Mar 19, 2025 06:02am
- Takeda Pharmaceuticals Korea announced on the 18th that it has appointed Kwang-kyu Park as its new General Manager as of March 17, 2025. Park is a pharmaceutical industry expert with more than 20 years of experience in the industry and strong expertise and leadership in Specialty Care and Oncology (hematologic malignancies and immunotherap
- Policy
- Drug briefing on Enhertu's NSCLC reimb has been requested
- by Lee, Tak-Sun Mar 19, 2025 06:02am
- It has been reported that Daiichi Sankyo, which is aiming for Enhertu (trastuzumab deruxtecan)'s expanded reimbursement for HER2-mutant non-small cell lung cancer (NSCLC), will hold a drug briefing session with the Health Insurance Review & Assessment Service (HIRA). In April 2024, Enhertu was added to the reimbursement listing in South K
- Company
- Ilaris can be prescribed in 7 hospitals in Korea
- by Eo, Yun-Ho Mar 19, 2025 06:01am
- The ultra-rare disease treatment 'Ilaris' may now be prescribed in more hospitals in Korea. According to industry sources, Novartis Korea's hereditary recurrent fever syndrome drug Ilaris (canakinumab) has passed the drug committees (DCs) of tertiary hospitals such as Seoul National University Hospital, Seoul St. Mary's Hospital, and Sinc
